Skip to main content

Advertisement

SpringerLink
Log in

The effects of 17β-estradiol plus drospirenone on anthropometric and biochemical measures of adiposity in menopausal women

  • General Gynecology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

To assess whether there are changes on anthropometric and biochemical measures of adiposity in pre- and postmenopausal women and in the latter before and after 6 months treatment with 17β-estradiol plus drospirenone.

Methods

Twenty postmenopausal and 20 premenopausal women were enrolled in a prospective comparative study. Postmenopausal women received 1 mg 17β-estradiol plus 2 mg drospirenone daily for 6 months. Measurements of body mass index (BMI), waist/hip ratio and plasmatic levels of insulin, glucose, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglyceride, leptin, adiponectin, orexin-A, glucagon-like peptide-1 (GLP-1) and ghrelin were performed in premenopausal (group 1) and postmenopausal women and in the latter before (group 2a) and after (group 2b) 6 months treatment with 17β-estradiol plus drospirenone.

Results

No significant changes in BMIs, insulin and glucose were observed between group 1 and 2a; and group 2a and 2b. GLP-1 levels were significantly increased in group 1 compared to group 2a (p = 0.035). Leptin levels were significantly increased (p = 0.001) and GLP-1 levels were significantly decreased (p = 0.021) in group 2b compared to group 2a. HDL was significantly decreased while LDL and triglyceride levels were significantly increased in group 2a compared to group 1. (p = 0.030, p = 0.001, p = 0.020; respectively) LDL was significantly decreased (p = 0.010) in group 2b compared to group 2a. GLP-1 had a positive correlation with orexin-A (p < 0.001, r = 0.520) and negative correlation with leptin (p = 0.008, r = −0.345).

Conclusion

Leptin was significantly higher and GLP-1 was significantly lower in women receiving 17β-estradiol plus drospirenone treatment. GLP-1 levels were significantly lower after the menopause compared to premenopausal levels. Orexin-A and GLP-1 were positively correlated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjöström L (1984) Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J 289:1261–1263

    Article  Google Scholar 

  2. Van der Kooy K, Leenen R, Seidell JC, Deurenberg P, Droop A, Bakker CJ (1993) Waist-hip ratio is a poor predictor of changes in visceral fat. Am J Clin Nutr 57:323–327

    Google Scholar 

  3. Perry AC, Allison M, Applegate EB, Jackson ML, Miller PC (1998) The relationship between fat distribution and coronary risk factors in sedentary postmenopausal women on and off hormone replacement therapy. Obesity Res 6:40–46

    CAS  Google Scholar 

  4. Lamarche B, Tchernof A, Moorjani S et al (1997) Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation 95:69–75

    Article  PubMed  CAS  Google Scholar 

  5. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL (1994) Increasing prevalence of overweight among US adults. A National Health and Nutrition Examination Survey, 1960–1991. JAMA 272:205–211

    Article  PubMed  CAS  Google Scholar 

  6. Sowers M, Zheng H, Tomey K et al (2007) Changes in body composition in women over 6 years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab 92:895–901

    Article  PubMed  CAS  Google Scholar 

  7. Guthrie JR, Dennerstein L, Taffe JR et al (2003) Central abdominal fat and endogenous hormones during the menopausal transition. Fertil Steril 79:1335–1340

    Article  PubMed  Google Scholar 

  8. Svendsen OL, Hassager C, Christiansen C (1993) Relationships and independence of body composition, sex hormones, fat distribution and other cardiovascular risk factors in overweight postmenopausal women. Int J Obes 17:459–463

    CAS  Google Scholar 

  9. Gallagher D, Visser M, Sepulveda D, Pierson RN Jr, Harris T, Heymsfield SB (1996) How useful body mass index for comparison of body fatness across age, gender and ethnic groups? Am J Epidemiol 143:228–239

    Article  PubMed  CAS  Google Scholar 

  10. Considine RV, Sinha MK, Heiman ML et al (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292–295

    Article  PubMed  CAS  Google Scholar 

  11. Lee CG, Carr MC, Murdoch SJ et al (2009) Adipokines, inflammation, and visceral adiposity across the menopausal transition: a prospective study. J Clin Endocrinol Metab 94:1104–1110

    Article  PubMed  CAS  Google Scholar 

  12. Bednarek-Tupikowska G, Filus A, Kuliczkowska-Płaksej J, Tupikowski K, Bohdanowicz-Pawlak A, Milewicz A (2006) Serum leptin concentrations in pre- and postmenopausal women on sex hormone therapy. Gynecol Endocrinol 22:207–212

    Article  PubMed  CAS  Google Scholar 

  13. Lambrinoudaki IV, Christodoulakos GE, Economou EV et al (2008) Circulating leptin and ghrelin are differentially influenced by estrogen/progestin therapy and raloxifene. Maturitas 59:62–71

    Article  PubMed  CAS  Google Scholar 

  14. Dedeoğlu EN, Erenus M, Yörük P (2009) Effects of hormone therapy and tibolone on body composition and serum leptin levels in postmenopausal women. Fertil Steril 91:425–431

    Article  PubMed  Google Scholar 

  15. Milewicz A, Zatonska K, Demissie M et al (2005) Serum adiponectin concentration and cardiovascular risk factors in climacteric women. Gynecol Endocrinol 20:68–73

    Article  PubMed  CAS  Google Scholar 

  16. Sieminska L, Wojciechowska C, Niedziolka D et al (2005) Effect of postmenopause and hormone replacement therapy on serum adiponectin levels. Metabolism 54:1610–1614

    Article  PubMed  CAS  Google Scholar 

  17. Im JA, Lee JW, Lee HR, Lee DC (2006) Plasma adiponectin levels in postmenopausal women with or without long-term hormone. Maturitas 54:65–71

    Article  PubMed  CAS  Google Scholar 

  18. Lou XM, Duan GC, Chen J, Zhou Y, Hu QY, Heng ZC (2006) Blood leptin, orexins and NPY levels and their relations in obese children. Sichuan Da Xue Xue Bao Yi Xue Ban. 37:621–624

    PubMed  CAS  Google Scholar 

  19. Matsumura T, Nakayama M, Satoh H, Naito A, Kamahara K, Sekizawa K (2003) Composition in COPD plasma orexin-A levels and body. Chest 123:1060–1065

    Article  PubMed  CAS  Google Scholar 

  20. Smart D, Haynes AC, Williams G, Arch JR (2002) Orexins and the treatment of obesity. Eur J Pharmacol 440:199–212

    Article  PubMed  CAS  Google Scholar 

  21. Whatmore AJ, Hall CM, Jones J, Westwood M, Clayton PE (2003) Ghrelin concentrations in healthy children and adolescents. Clin Endocrinol (Oxf). 59:649–654

    Article  CAS  Google Scholar 

  22. Iwamoto I, Yoshimitsu N, Fujino T, Douchi T (2005) Menopausal status influences the relationship between serum ghrelin levels and fat mass in healthy women. Endocrinol Invest. 28:405–409

    CAS  Google Scholar 

  23. Di Carlo C, Tommaselli GA, Gargano V, Sammartino A, Bifulco G, Tauchmanova L (2007) Effects of estrogen-progestin therapy on serum levels of RANKL, osteoprotegerin, osteocalcin, leptin, and ghrelin in postmenopausal women. Menopause 14:38–44

    Article  PubMed  Google Scholar 

  24. Ranganath L, Sedgwick I, Morgan L, Wright J, Marks V (1998) The ageing entero-insular axis. Diabetologia 41:1309–1313

    Article  PubMed  CAS  Google Scholar 

  25. Korosi J, McIntosh CH, Pederson RA et al (2001) Effect of aging and diabetes on the enteroinsular axis. J Gerontol A Biol Sci Med Sci 56:M575–M579

    Article  PubMed  CAS  Google Scholar 

  26. Hellström PM, Geliebter A, Näslund E, Schmidt PT, Yahav EK, Hashim SA, Yeomans MR (2004) Peripheral and central signals in the control of eating in normal, obese and binge-eating human subjects. Br J Nutr 92 Suppl 1:S47–S57

    Article  PubMed  Google Scholar 

  27. Hulley S, Grady D, Bush T et al (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280:605–613

    Article  PubMed  CAS  Google Scholar 

  28. Ravassa S, Zudaire A, Díez J (2012) GLP-1 and cardioprotection: from bench to bedside. Cardiovasc Res 94(2):316–323

    Article  PubMed  CAS  Google Scholar 

  29. Read PA, Khan FZ, Dutka DP (2012) Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart 98(5):408–413

    Article  PubMed  CAS  Google Scholar 

  30. Fields AV, Patterson B, Karnik AA, Shannon RP (2009) Glucagon-like peptide-1 and myocardial protection: more than glycemic control. Clin Cardiol 32(5):236–243

    Article  PubMed  Google Scholar 

  31. Saraceni C, Broderick TL (2007) Effects of glucagon-like peptide-1 and long-acting analogues on cardiovascular and metabolic function. Drugs R D 8(3):145–153 Review

    Article  PubMed  CAS  Google Scholar 

  32. Kantorova E, Chomova M, Kurca E, Sivak S, Zelenak K, Kučera P, Galajda P (2011) Leptin, adiponectin and ghrelin, new potential mediators of ischemic stroke. Neuro Endocrinol Lett. 32(5):716–721

    PubMed  CAS  Google Scholar 

  33. Smith CC, Dixon RA, Wynne AM, Theodorou L, Ong SG, Subrayan S, Davidson SM, Hausenloy DJ, Yellon DM (2010) Leptin-induced cardioprotection involves JAK/STAT signaling that may be linked to the mitochondrial permeability transition pore. Am J Physiol Heart Circ Physiol 299(4):H1265–H1270

    Article  PubMed  CAS  Google Scholar 

  34. Design of the Women’s Health Initiative clinical trial and observational study (1998) The Women’s Health Initiative Study Group. Control Clin Trials 19:61–109

    Article  Google Scholar 

  35. Rossouw JE, Anderson GL, Prentice RL et al (2002) Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288:321–323

    Article  PubMed  CAS  Google Scholar 

  36. Al-Azzawi F, Wahab M, Sami S, Proudler AJ, Thompson J, Stevenson J (2004) Randomized trial of effects of estradiol in combination with either norethisterone acetate or trimegestone on lipids and lipoproteins in postmenopausal women. Climacteric. 7:292–300

    Article  PubMed  CAS  Google Scholar 

  37. Saranyaratana W, Sakondhavat C, Silaruks S, Soontrapa S, Kaewrudee S (2006) Effect of hormone therapy on lipid profile in menopausal women. J Med Assoc Thai 89(Suppl 4):S37–S41

    PubMed  Google Scholar 

  38. Dias AR Jr, Melo RN, Gebara OC et al (2005) Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women. Climacteric. 8:63–70

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by the Research Fund of Istanbul University (Project number: T-1925/2008).

Conflict of interest

The authors declare that they have no conflict of interest related to the publication of this manuscript.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey

    Mesut Karakus, Onur Guralp, Deniz Topcuoglu & Seyfettin Uludag

  2. Department of Medical Biochemistry, Cerrahpasa Medical Faculty, Istanbul University, 34303, Cerrahpaşa, Istanbul, Turkey

    Remise Gelisgen & Hafize Uzun

  3. Department of Physiology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey

    Gonul Simsek

  4. Department of Obstetrics and Gynecology, Faculty of Medicine, Izzet Baysal University, Bolu, Turkey

    Ata Topcuoglu

Authors
  1. Mesut Karakus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Remise Gelisgen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ata Topcuoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Onur Guralp
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Deniz Topcuoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gonul Simsek
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Seyfettin Uludag
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hafize Uzun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hafize Uzun.

Additional information

H. Uzun and R. Gelisgen contributed equally to the research and writing of this manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karakus, M., Gelisgen, R., Topcuoglu, A. et al. The effects of 17β-estradiol plus drospirenone on anthropometric and biochemical measures of adiposity in menopausal women. Arch Gynecol Obstet 286, 1233–1239 (2012). https://doi.org/10.1007/s00404-012-2437-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-012-2437-9

Keywords

Search

Navigation